{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:24:20Z","timestamp":1747207460470,"version":"3.40.5"},"reference-count":87,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHAMC"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Statin drugs have long been used as a key component of lipid-lowering therapy, which\nis necessary for the prevention and treatment of atherosclerosis and cardiovascular diseases. Many\nstudies focus on finding and refining new effects of statin drugs. In addition to the main lipidlowering\neffect (blocking cholesterol synthesis), statin drugs have a number of pleiotropic effects,\nincluding negative effects. The main beneficial effects of statin drugs on the components of the\ncardiovascular system are: anti-ischemic, antithrombotic, anti-apoptotic, antioxidant, endothelioprotective,\nanti-inflammatory properties, and a number of other beneficial effects. Due to these\neffects, statin drugs are considered one of the main therapeutic agents for the management of patients\nwith cardiovascular pathologies. To date, many review manuscripts have been published on\nthe myotoxicity, hepatotoxicity, nephrotoxicity, neurotoxicity and diabetogenic effects of statins.\nHowever, there are no review manuscripts considering the negative effect of statin drugs on myocardial\ncontractile cells (cardiomyocytes). The purpose of this review is to discuss the negative\neffects of statin drugs on cardiomyocytes. Special attention is paid to the cardiotoxic action of\nstatin drugs on cardiomyocytes and the mechanisms of increased serum levels of cardiac troponins.\nIn the process of preparing this review, a detailed analysis of laboratory and experimental\ndata devoted to the study of the negative effects of statin drugs on cardiomyocytes was carried out.\nThe literature search was carried out with the keywords: statin drugs, negative effects, mechanisms,\ncardiac troponins, oxidative stress, apoptosis. Thus, statin drugs can have a number of\nnegative effects on cardiomyocytes, in particular, increased oxidative stress, endoplasmic reticulum\nstress, damage to mitochondria and intercalated discs, and inhibition of glucose transport into\ncardiomyocytes. Additional studies are needed to confirm and clarify the mechanisms and clinical\nconsequences of the negative effects of statin drugs on cardiomyocytes.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871525721666230314101019","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:29:42Z","timestamp":1678858182000},"page":"7-16","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Negative Effects of Statin Drugs on Cardiomyocytes: Current Review\nof Laboratory and Experimental Data (Mini-Review)"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-0227","authenticated-orcid":true,"given":"Aleksey Michailovich","family":"Chaulin","sequence":"first","affiliation":[{"name":"Department of Cardiology and Cardiovascular Surgery, Samara State Medical University, Samara, 443099, Russia"},{"name":"Department of Histology and Embryology, Samara State Medical University, Samara, 443099, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"85","volume":"39","author":"Ageev A.K.","year":"1977","unstructured":"Ageev A.K.; Life and career of N. N. Anichkov--outstanding Soviet pathologist (on the 30th anniversary of the electron of N. N. Anichkov to the presidency of the Academy of Medical Sciences of the USSR). Arkh Patol 1977,39(4),85-89","journal-title":"Arkh Patol"},{"key":"ref=2","first-page":"3","volume":"37","author":"Klimov A.N.","year":"1975","unstructured":"Klimov A.N.; Sinitsyna T.A.; Nagornev V.A.; Development of the ideas of N. N. Anichkov at the present stage of our knowledge about atherosclerosis. Arkh Patol 1975,37(11),3-16","journal-title":"Arkh Patol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2183\/pjab.86.484","volume":"86","author":"Endo A.","year":"2010","unstructured":"Endo A.; A historical perspective on the discovery of statins. Proc Jpn Acad, Ser B, Phys Biol Sci 2010,86(5),484-493","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1586\/erc.10.113","volume":"8","author":"Nair P.K.","year":"2010","unstructured":"Nair P.K.; Mulukutla S.R.; Marroquin O.C.; Stents and statins: History, clinical outcomes and mechanisms. Expert Rev Cardiovasc Ther 2010,8(9),1283-1295","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosissup.2004.08.026","volume":"5","author":"Endo A.","year":"2004","unstructured":"Endo A.; The discovery and development of HMG-CoA reductase inhibitors. Atheroscler Suppl 2004,5(3),67-80","journal-title":"Atheroscler Suppl"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"Chou R.","year":"2016","unstructured":"Chou R.; Dana T.; Blazina I.; Daeges M.; Jeanne T.L.; Statins for prevention of cardiovascular disease in adults. JAMA 2016,316(19),2008-2024","journal-title":"JAMA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jama.2022.13493","volume":"328","author":"Jin J.","year":"2022","unstructured":"Jin J.; Statins for the prevention of cardiovascular disease. JAMA 2022,328(8),786","journal-title":"JAMA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2174\/138161211795428803","volume":"17","author":"Berthold H.K.","year":"2011","unstructured":"Berthold H.K.; Gouni-Berthold I.; Lipid-lowering drug therapy in elderly patients. Curr Pharm Des 2011,17(9),877-893","journal-title":"Curr Pharm Des"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/1573403X13666170918165713","volume":"13","author":"Mikhail N.","year":"2017","unstructured":"Mikhail N.; Effects of evolocumab on cardiovascular events. Curr Cardiol Rev 2017,13(4),319-324","journal-title":"Curr Cardiol Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1389557518666180423111442","volume":"19","author":"Wang Y.","year":"2018","unstructured":"Wang Y.; Liu Z.P.; PCSK9 inhibitors: Novel therapeutic strategies for lowering ldlcholesterol. Mini Rev Med Chem 2018,19(2),165-176","journal-title":"Mini Rev Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jacl.2017.05.016","volume":"11","author":"Farnier M.","year":"2017","unstructured":"Farnier M.; Colhoun H.M.; Sasiela W.J.; Edelberg J.M.; Asset G.; Robinson J.G.; Long-term treatment adherence to the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. J Clin Lipidol 2017,11(4),986-997","journal-title":"J Clin Lipidol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5551\/jat.55400","volume":"27","author":"Yurtseven E.","year":"2020","unstructured":"Yurtseven E.; Ural D.; Baysal K.; Tokg\u00f6zo\u011flu L.; An update on the role of PCSK9 in atherosclerosis. J Atheroscler Thromb 2020,27(9),909-918","journal-title":"J Atheroscler Thromb"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.17816\/RCF19137-46","volume":"19","author":"Chaulin A.M.","year":"2021","unstructured":"Chaulin A.M.; Hypolipidemic drugs inhibiting the proprotein convertase of subtilisin\/kexin type 9 (PCSK9): Monoclonal antibodies, antisense oligonucleotides, small interfering ribonucleic acids. Rev. Clinic. Pharmacol Drug Therapy 2021,19(1),37-46","journal-title":"Pharmacol Drug Therapy"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e0169761","DOI":"10.1371\/journal.pone.0169761","volume":"12","author":"Arrieta A.","year":"2017","unstructured":"Arrieta A.; Page T.F.; Veledar E.; Nasir, K Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One 2017,12(1),e0169761","journal-title":"PLoS One"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11883-010-0147-y","volume":"13","author":"Lardizabal J.A.","year":"2011","unstructured":"Lardizabal J.A.; Deedwania P.C.; The anti-ischemic and anti-anginal properties of statins. Curr Atheroscler Rep 2011,13(1),43-50","journal-title":"Curr Atheroscler Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-med-051812-145304","volume":"65","author":"Phillip Owens A.","year":"2014","unstructured":"Phillip Owens A.; Mackman N.; The antithrombotic effects of statins. Annu Rev Med 2014,65(1),433-445","journal-title":"Annu Rev Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.18097\/pbmc20206605357","volume":"66","author":"Tursunova N.V.","year":"2020","unstructured":"Tursunova N.V.; Klinnikova M.G.; Babenko O.A.; Lushnikova E.L.; Molecular mechanisms of the cardiotoxic action of anthracycline antibiotics and statin-induced cytoprotective reactions of cardiomyocytes. Biomed Khim 2020,66(5),357-371","journal-title":"Biomed Khim"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1440-1681.2004.04010.x","volume":"31","author":"Tanaka K.","year":"2004","unstructured":"Tanaka K.; Honda M.; Takabatake T.; Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 2004,31(5-6),360-364","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","volume":"60","author":"Koushki K.","year":"2021","unstructured":"Koushki K.; Shahbaz S.K.; Mashayekhi K.; Sadeghi M.; Zayeri Z.D.; Taba M.Y.; Banach M.; Al-Rasadi K.; Johnston T.P.; Sahebkar A.; Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol 2021,60(2),175-199","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1515\/aiht-2017-68-2994","volume":"68","author":"Karahalil B.","year":"2017","unstructured":"Karahalil B.; Hare E.; Ko\u00e7 G.; Uslu \u0130.; \u015eent\u00fcrk K.; \u00d6zkan Y.; Hepatotoxicity associated with statins. Arh Hig Rada Toksikol 2017,68(4),254-260","journal-title":"Arh Hig Rada Toksikol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11883-019-0780-z","volume":"21","author":"Carmena R.","year":"2019","unstructured":"Carmena R.; Betteridge D.J.; Diabetogenic action of statins: Mechanisms. Curr Atheroscler Rep 2019,21(6),23","journal-title":"Curr Atheroscler Rep"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2015.194","volume":"12","author":"Betteridge D.J.","year":"2016","unstructured":"Betteridge D.J.; Carmena R.; The diabetogenic action of statins \u2014 mechanisms and clinical implications. Nat Rev Endocrinol 2016,12(2),99-110","journal-title":"Nat Rev Endocrinol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/2047487314550804","volume":"23","author":"Auer J.","year":"2016","unstructured":"Auer J.; Sinzinger H.; Franklin B.; Berent R.; Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur J Prev Cardiol 2016,23(1),88-110","journal-title":"Eur J Prev Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ccl.2015.02.008","volume":"33","author":"Rojas-Fernandez C.","year":"2015","unstructured":"Rojas-Fernandez C.; Hudani Z.; Bittner V.; Statins and cognitive side effects: What cardiologists need to know. Cardiol Clin 2015,33(2),245-256","journal-title":"Cardiol Clin"},{"journal-title":"Available from","year":"2022","key":"ref=25","unstructured":"Available from 2022"},{"key":"ref=26","unstructured":"https:\/\/www.nobelprize.org\/prizes\/chemistry\/1965\/woodward\/facts\/"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"Sirtori C.R.","year":"2014","unstructured":"Sirtori C.R.; The pharmacology of statins. Pharmacol Res 2014,88,3-11","journal-title":"Pharmacol Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1185\/03007990152005388","volume":"17","author":"Wierzbicki A.S.","year":"2001","unstructured":"Wierzbicki A.S.; Synthetic statins: More data on newer lipid-lowering agents. Curr Med Res Opin 2001,17(1),74-77","journal-title":"Curr Med Res Opin"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.13040\/IJPSR.0975-8232.7(8).3197-07","volume":"7","author":"Selvasudha N.","year":"2016","unstructured":"Selvasudha N.; Koumaravelou K.; Statin induced myotoxicity and its consequences - an overview. Int J Pharm Sci Res 2016,7(8),3197-07","journal-title":"Int J Pharm Sci Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1592\/phco.30.6.541","volume":"30","author":"Cham S.","year":"2010","unstructured":"Cham S.; Evans M.A.; Denenberg J.O.; Golomb B.A.; Statin-associated muscle-related adverse effects: A case series of 354 patients. Pharmacotherapy 2010,30(6),541-553","journal-title":"Pharmacotherapy"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.33678\/cor.2021.041","volume":"63","author":"Chaulin A.M.","year":"2021","unstructured":"Chaulin A.M.; Duplyakov D.V.; Cardiac troponins: Current data on the diagnostic value and analytical characteristics of new determination methods. Cor Vasa 2021,63(4),486-493","journal-title":"Cor Vasa"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.34883\/PI.2022.11.1.018","volume":"11","author":"Chaulin A.","year":"2022","unstructured":"Chaulin A.; Duplyakov D.; Analytical Review of Modern Information on the Physiological and Pathochemical Mechanisms of the Release of Cardiospecific Proteins from Muscle Tissue, Methodology and Technologies of Their Research, Interpretation of the Results. Laboratory Diagnostics. Eastern Europe 2022,11(1),78-97","journal-title":"Eastern Europe"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/0002-8703(87)90645-4","volume":"113","author":"Cummins B.","year":"1987","unstructured":"Cummins B.; Auckland M.L.; Cummins P.; Cardiac-specific troponin-l radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987,113(6),1333-1344","journal-title":"Am Heart J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/0022-2828(89)90680-9","volume":"21","author":"Katus H.","year":"1989","unstructured":"Katus H.; Remppis A.; Looser S.; Hallermeier K.; Scheffold T.; K\u00fcbler W.; Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989,21(12),1349-1353","journal-title":"J Mol Cell Cardiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/VHRM.S300002","volume":"17","author":"Chaulin A.","year":"2021","unstructured":"Chaulin A.; Cardiac troponins: Contemporary biological data and new methods of determination. Vasc Health Risk Manag 2021,17,299-316","journal-title":"Vasc Health Risk Manag"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrcardio.2017.48","volume":"14","author":"Westermann D.","year":"2017","unstructured":"Westermann D.; Neumann J.T.; S\u00f6rensen N.A.; Blankenberg S.; High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol 2017,14(8),472-483","journal-title":"Nat Rev Cardiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/VHRM.S315376","volume":"17","author":"Chaulin A.","year":"2021","unstructured":"Chaulin A.; Clinical and diagnostic value of highly sensitive cardiac troponins in arterial hypertension. Vasc Health Risk Manag 2021,17,431-443","journal-title":"Vasc Health Risk Manag"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cca.2018.08.015","volume":"486","author":"Garcia-Osuna A.","year":"2018","unstructured":"Garcia-Osuna A.; Gaze D.; Grau-Agramunt M.; Morris T.; Telha C.; Bartolome A.; Bishop J.J.; Monsalve L.; Livingston R.; Estis J.; Nolan N.; Sandlund J.; Ordonez-Llanos J.; Ultrasensitive quantification of cardiac troponin I by a Single Molecule Counting method: Analytical validation and biological features. Clin Chim Acta 2018,486,224-231","journal-title":"Clin Chim Acta"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jacc.2013.12.032","volume":"63","author":"Gore M.O.","year":"2014","unstructured":"Gore M.O.; Seliger S.L.; deFilippi C.R.; Nambi V.; Christenson R.H.; Hashim I.A.; Hoogeveen R.C.; Ayers C.R.; Sun W.; McGuire D.K.; Ballantyne C.M.; de Lemos J.A.; Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol 2014,63(14),1441-1448","journal-title":"J Am Coll Cardiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.clinbiochem.2017.11.003","volume":"52","author":"Trupp R.J.","year":"2018","unstructured":"Trupp R.J.; Albert G.; Ziegler A.; Sex-specific 99th percentiles derived from the AACC Universal Sample Bank for the Roche Gen 5 cTnT assay: Comorbidities and statistical methods influence derivation of reference limits. Clin Biochem 2018,52,173","journal-title":"Clin Biochem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1373\/clinchem.2018.298059","volume":"65","author":"Anand A.","year":"2019","unstructured":"Anand A.; Shah A.S.V.; Beshiri A.; Jaffe A.S.; Mills N.L.; Global adoption of high-sensitivity cardiac troponins and the universal definition of myocardial infarction. Clin Chem 2019,65(3),484-489","journal-title":"Clin Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.15829\/1560-4071-2020-4061","volume":"25","author":"Chaulin A.M.","year":"2020","unstructured":"Chaulin A.M.; Duplyakova P.D.; Duplyakov D.V.; Circadian rhythms of cardiac troponins: Mechanisms and clinical significance. Russ J Cardiol 2020,25(3S),4061","journal-title":"Russ J Cardiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.3390\/jcm9123917","volume":"9","author":"Chen J.Y.","year":"2020","unstructured":"Chen J.Y.; Lee S.Y.; Li Y.H.; Lin C.Y.; Shieh M.D.; Ciou D.S.; Urine high-sensitivity troponin I predict incident cardiovascular events in patients with diabetes mellitus. J Clin Med 2020,9(12),3917","journal-title":"J Clin Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.22514\/SV133.062017.13","volume":"13","author":"Pervan P.","year":"2017","unstructured":"Pervan P.; Svagu\u0161a T.; Prka\u010din I.; Savuk A.; Bakos M.; Perkov S.; Urine high sensitive Troponin I measuring in patients with hypertension. Signa Vitae 2017,13(S3),62-64","journal-title":"Signa Vitae"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1601-0825.2012.01968.x","volume":"19","author":"Mirzaii-Dizgah I.","year":"2013","unstructured":"Mirzaii-Dizgah I.; Riahi E.; Salivary high-sensitivity cardiac troponin T levels in patients with acute myocardial infarction. Oral Dis 2013,19(2),180-184","journal-title":"Oral Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.18087\/cardio.2019.11.n414","volume":"59","author":"Chaulin A.M.","year":"2019","unstructured":"Chaulin A.M.; Karslyan L.S.; Bazyuk E.V.; Nurbaltaeva D.A.; Duplyakov D.V.; Clinical and diagnostic value of cardiac markers in human biological fluids. Kardiologiia 2019,59(11),66-75","journal-title":"Kardiologiia"},{"key":"ref=47","first-page":"354","volume":"68","author":"Klichowska-Palonka M.","year":"2015","unstructured":"Klichowska-Palonka M.; Za\u0142\u0119ska-Chromi\u0144ska K.; Bachanek T.; Possibility of using saliva as a diagnostic test material in cardiovascular diseases. Wiad Lek 2015,68(3 pt 2),354-357","journal-title":"Wiad Lek"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.15829\/1560-4071-2020-3814","volume":"25","author":"Chaulin A.M.","year":"2020","unstructured":"Chaulin A.M.; Duplyakova P.D.; Bikbaeva G.R.; Tukhbatova A.A.; Grigorieva E.V.; Duplyakov D.V.; Concentration of high-sensitivity cardiac troponin I in the oral fluid in patients with acute myocardial infarction: A pilot study. Russ J Cardiol 2020,25(12),3814","journal-title":"Russ J Cardiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/biology11030429","volume":"11","author":"Chaulin A.M.","year":"2022","unstructured":"Chaulin A.M.; Biology of cardiac troponins: Emphasis on metabolism. Biology 2022,11(3),429","journal-title":"Biology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s00392-017-1152-8","volume":"106","author":"Fournier S.","year":"2017","unstructured":"Fournier S.; Iten L.; Marques-Vidal P.; Boulat O.; Bardy D.; Beggah A.; Calderara R.; Morawiec B.; Lauriers N.; Monney P.; Iglesias J.F.; Pascale P.; Harbaoui B.; Eeckhout E.; Muller O.; Circadian rhythm of blood cardiac troponin T concentration. Clin Res Cardiol 2017,106(12),1026-1032","journal-title":"Clin Res Cardiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e0305","DOI":"10.15275\/rusomj.2020.0305","volume":"9","author":"Chaulin A.M.","year":"2020","unstructured":"Chaulin A.M.; Abashina O.E.; Duplyakov D.V.; Pathophysiological mechanisms of cardiotoxicity in chemotherapeutic agents. Russ Open Med J 2020,9,e0305","journal-title":"Russ Open Med J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cca.2020.02.004","volume":"504","author":"Zaninotto M.","year":"2020","unstructured":"Zaninotto M.; Padoan A.; Mion M.M.; Marinova M.; Plebani M.; Short-term biological variation and diurnal rhythm of cardiac troponin I (Access hs-TnI) in healthy subjects. Clin Chim Acta 2020,504,163-167","journal-title":"Clin Chim Acta"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e0311","DOI":"10.15275\/rusomj.2021.0311","volume":"10","author":"Chaulin A.M.","year":"2021","unstructured":"Chaulin A.M.; Grigorieva J.V.; Suvorova G.N.; Duplyakov D.V.; Experimental Modeling Of Hypothyroidism: Principles, Methods, Several Advanced Research Directions In Cardiology. Russian Open Med J 2021,10(3),e0311","journal-title":"Russian Open Med J"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.18087\/cardio.2506","volume":"59","author":"Tsareva Y.O.","year":"2019","unstructured":"Tsareva Y.O.; Mayskova E.A.; Fedotov E.A.; Shvarts Y.G.; Circadian rhythms of thyroid hormones in patients with ischemic heart disease, arterial hypertension, and atrial fibrillation. Kardiologiia 2019,59(3S),23-29","journal-title":"Kardiologiia"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/00015385.2018.1510801","volume":"74","author":"\u00dcnl\u00fc S.","year":"2019","unstructured":"\u00dcnl\u00fc S.; Nurko\u00e7 S.G.; Sezen\u00f6z B.; Cingirt M.; G\u00fclbahar \u00d6.; Abac\u0131 A.; Impact of statin use on high sensitive troponin T levels with moderate exercise. Acta Cardiol 2019,74(5),380-385","journal-title":"Acta Cardiol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.22514\/sv.2021.050","volume":"17","author":"Chaulin A.M.","year":"2021","unstructured":"Chaulin A.M.; Duplyakov D.V.; On the potential effect of circadian rhythms of cardiac troponins on the diagnosis of acute myocardial infarction. Signa Vitae 2021,17,79-84","journal-title":"Signa Vitae"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Collet J.P.","year":"2021","unstructured":"Collet J.P.; Thiele H.; Barbato E.; Barth\u00e9l\u00e9my O.; Bauersachs J.; Bhatt D.L.; Dendale P.; Dorobantu M.; Edvardsen T.; Folliguet T.; Gale C.P.; Gilard M.; Jobs A.; J\u00fcni P.; Lambrinou E.; Lewis B.S.; Mehilli J.; Meliga E.; Merkely B.; Mueller C.; Roffi M.; Rutten F.H.; Sibbing D.; Siontis G.C.M.; Kastrati A.; Mamas M.A.; Aboyans V.; Angiolillo D.J.; Bueno H.; Bugiardini R.; Byrne R.A.; Castelletti S.; Chieffo A.; Cornelissen V.; Crea F.; Delgado V.; Drexel H.; Gierlotka M.; Halvorsen S.; Haugaa K.H.; Jankowska E.A.; Katus H.A.; Kinnaird T.; Kluin J.; Kunadian V.; Landmesser U.; Leclercq C.; Lettino M.; Meinila L.; Mylotte D.; Ndrepepa G.; Omerovic E.; Pedretti R.F.E.; Petersen S.E.; Petronio A.S.; Pontone G.; Popescu B.A.; Potpara T.; Ray K.K.; Luciano F.; Richter D.J.; Shlyakhto E.; Simpson I.A.; Sousa-Uva M.; Storey R.F.; Touyz R.M.; Valgimigli M.; Vranckx P.; Yeh R.W.; Barbato E.; Barth\u00e9l\u00e9my O.; Bauersachs J.; Bhatt D.L.; Dendale P.; Dorobantu M.; Edvardsen T.; Folliguet T.; Gale C.P.; Gilard M.; Jobs A.; J\u00fcni P.; Lambrinou E.; Lewis B.S.; Mehilli J.; Meliga E.; Merkely B.; Mueller C.; Roffi M.; Rutten F.H.; Sibbing D.; Siontis G.C.M.; 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021,42(14),1289-1367","journal-title":"Eur Heart J"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"Thygesen K.","year":"2019","unstructured":"Thygesen K.; Alpert J.S.; Jaffe A.S.; Chaitman B.R.; Bax J.J.; Morrow D.A.; White H.D.; Thygesen K.; Alpert J.S.; Jaffe A.S.; Chaitman B.R.; Bax J.J.; Morrow D.A.; White H.D.; Mickley H.; Crea F.; Van de Werf F.; Bucciarelli-Ducci C.; Katus H.A.; Pinto F.J.; Antman E.M.; Hamm C.W.; De Caterina R.; Januzzi J.L.; Apple F.S.; Alonso Garcia M.A.; Underwood S.R.; Canty J.M.; Lyon A.R.; Devereaux P.J.; Zamorano J.L.; Lindahl B.; Weintraub W.S.; Newby L.K.; Virmani R.; Vranckx P.; Cutlip D.; Gibbons R.J.; Smith S.C.; Atar D.; Luepker R.V.; Robertson R.M.; Bonow R.O.; Steg P.G.; O\u2019Gara P.T.; Fox K.A.A.; Hasdai D.; Aboyans V.; Achenbach S.; Agewall S.; Alexander T.; Avezum A.; Barbato E.; Bassand J-P.; Bates E.; Bittl J.A.; Breithardt G.; Bueno H.; Bugiardini R.; Cohen M.G.; Dangas G.; de Lemos J.A.; Delgado V.; Filippatos G.; Fry E.; Granger C.B.; Halvorsen S.; Hlatky M.A.; Ibanez B.; James S.; Kastrati A.; Leclercq C.; Mahaffey K.W.; Mehta L.; M\u00fcller C.; Patrono C.; Piepoli M.F.; Pi\u00f1eiro D.; Roffi M.; Rubboli A.; Sharma S.; Simpson I.A.; Tendera M.; Valgimigli M.; van der Wal A.C.; Windecker S.; Chettibi M.; Hayrapetyan H.; Roithinger F.X.; Aliyev F.; Sujayeva V.; Claeys M.J.; Smaji\u0107 E.; Kala P.; Iversen K.K.; El Hefny E.; Marandi T.; Porela P.; Antov S.; Gilard M.; Blankenberg S.; Davlouros P.; Gudnason T.; Alcalai R.; Colivicchi F.; Elezi S.; Baitova G.; Zakke I.; Gustiene O.; Beissel J.; Dingli P.; Grosu A.; Damman P.; Julieb\u00f8 V.; Legutko J.; Morais J.; Tatu-Chitoiu G.; Yakovlev A.; Zavatta M.; Nedeljkovic M.; Radsel P.; Sionis A.; Jemberg T.; M\u00fcller C.; Abid L.; Abaci A.; Parkhomenko A.; Corbett S.; Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019,40(3),237-269","journal-title":"Eur Heart J"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.11613\/BM.2019.010703","volume":"29","author":"Trentini A.","year":"2019","unstructured":"Trentini A.; Manfrinato M.C.; Bellini T.; Volta C.A.; Hanau S.; Dalla Corte F.; Cervellati C.; Rosta V.; Spadaro S.; Fast skeletal troponin I, but not the slow isoform, is increased in patients under statin therapy: A pilot study. Biochem Med 2019,29(1),68-76","journal-title":"Biochem Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.amjcard.2014.05.047","volume":"114","author":"Eijsvogels T.M.H.","year":"2014","unstructured":"Eijsvogels T.M.H.; Januzzi J.L.; Taylor B.A.; Isaacs S.K.; D\u2019Hemecourt P.; Zaleski A.; Dyer S.; Troyanos C.; Weiner R.B.; Thompson P.D.; Baggish A.L.; Impact of statin use on exercise-induced cardiac troponin elevations. Am J Cardiol 2014,114(4),624-628","journal-title":"Am J Cardiol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/jalm\/jfaa031","volume":"5","author":"Collinson P.","year":"2020","unstructured":"Collinson P.; Kiely P.; Unexpected troponin elevation in a patient treated with atorvastatin. J Appl Lab Med 2020,5(4),798-801","journal-title":"J Appl Lab Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jacc.2018.01.070","volume":"71","author":"Schmid J.","year":"2018","unstructured":"Schmid J.; Liesinger L.; Birner-Gruenberger, R Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll Cardiol 2018,71(14),1540-1549","journal-title":"J Am Coll Cardiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/clinchem\/45.12.2129","volume":"45","author":"Ricchiuti V.","year":"1999","unstructured":"Ricchiuti V.; Apple F.S.; RNA expression of cardiac troponin T isoforms in diseased human skeletal muscle. Clin Chem 1999,45(12),2129-2135","journal-title":"Clin Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1309\/8KCL-UQRF-6EEL-36XK","volume":"114","author":"Messner B.","year":"2000","unstructured":"Messner B.; Baum H.; Fischer P.; Quasthoff S.; Neumeier D.; Expression of messenger RNA of the cardiac isoforms of troponin T and I in myopathic skeletal muscle. Am J Clin Pathol 2000,114(4),544-549","journal-title":"Am J Clin Pathol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCGENETICS.115.001322","volume":"9","author":"Wens S.C.A.","year":"2016","unstructured":"Wens S.C.A.; Schaaf G.J.; Michels M.; Kruijshaar M.E.; van Gestel T.J.M.; in \u2019t Groen, S.; Pijnenburg, J.; Dekkers, D.H.W.; Demmers, J.A.A.; Verdijk, L.B.; Brusse, E.; van Schaik, R.H.N.; van der Ploeg, A.T.; van Doorn, P.A.; Pijnappel, W.W.M.P. Elevated plasma cardiac troponin T levels caused by skeletal muscle damage in pompe disease. Circ Cardiovasc Genet 2016,9(1),6-13","journal-title":"Circ Cardiovasc Genet"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.15829\/1728-8800-2021-2590","volume":"20","author":"Chaulin A.M.","year":"2021","unstructured":"Chaulin A.M.; Abashina O.E.; Duplyakov D.V.; High-sensitivity cardiac troponins: Detection and central analytical characteristics. Cardiovasc Ther Prev 2021,20(2),2590","journal-title":"Cardiovasc Ther Prev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jacc.2018.01.068","volume":"71","author":"Jaffe A.S.","year":"2018","unstructured":"Jaffe A.S.; Apple F.S.; Science moves slowly. J Am Coll Cardiol 2018,71(14),1550-1552","journal-title":"J Am Coll Cardiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"80","DOI":"10.14740\/jocmr4664","volume":"14","author":"Chaulin A.M.","year":"2022","unstructured":"Chaulin A.M.; False-positive causes in serum cardiac troponin levels. J Clin Med Res 2022,14(2),80-87","journal-title":"J Clin Med Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"10928","DOI":"10.3390\/ijms222010928","volume":"22","author":"Chaulin A.M.","year":"2021","unstructured":"Chaulin A.M.; Cardiac troponins metabolism: From biochemical mechanisms to clinical practice (Literature Review). Int J Mol Sci 2021,22(20),10928","journal-title":"Int J Mol Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1096\/fj.201800876R","volume":"33","author":"Godoy J.C.","year":"2019","unstructured":"Godoy J.C.; Niesman I.R.; Busija A.R.; Kassan A.; Schilling J.M.; Schwarz A.; Alvarez E.A.; Dalton N.D.; Drummond J.C.; Roth D.M.; Kararigas G.; Patel H.H.; Zemljic-Harpf A.E.; Atorvastatin, but not pravastatin, inhibits cardiac Akt\/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J 2019,33(1),1209-1225","journal-title":"FASEB J"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1172\/JCI43008","volume":"120","author":"Zhang D.","year":"2010","unstructured":"Zhang D.; Contu R.; Latronico M.V.G.; Zhang J.L.; Rizzi R.; Catalucci D.; Miyamoto S.; Huang K.; Ceci M.; Gu Y.; Dalton N.D.; Peterson K.L.; Guan K.L.; Brown J.H.; Chen J.; Sonenberg N.; Condorelli G.; MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest 2010,120(8),2805-2816","journal-title":"J Clin Invest"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.yjmcc.2016.05.013","volume":"97","author":"Zhu Y.","year":"2016","unstructured":"Zhu Y.; Zhang C.; Chen B.; Chen R.; Guo A.; Hong J.; Song L.S.; Cholesterol is required for maintaining T-tubule integrity and intercellular connections at intercalated discs in cardiomyocytes. J Mol Cell Cardiol 2016,97,204-212","journal-title":"J Mol Cell Cardiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.12659\/MSM.897047","volume":"22","author":"Jiang Z.","year":"2016","unstructured":"Jiang Z.; Yu B.; Li Y.; Effect of three statins on glucose uptake of cardiomyocytes and its mechanism. Med Sci Monit 2016,22,2825-2830","journal-title":"Med Sci Monit"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.17802\/2306-1278-2020-9-3-69-80","volume":"9","author":"Chaulin A.M.","year":"2020","unstructured":"Chaulin A.M.; Duplyakov D.V.; Arrhythmogenic effects of doxorubicin. Complex Issues of Cardiovascular Diseases 2020,9(3),69-80","journal-title":"Complex Issues of Cardiovascular Diseases"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"103","DOI":"10.20996\/1819-6446-2022-02-11","volume":"18","author":"Chaulin A.M.","year":"2022","unstructured":"Chaulin A.M.; Duplyakov D.V.; Cardioprotective strategies for doxorubicin-induced cardiotoxicity: Present and future. Ration Pharmacother Cardiol 2022,18(1),103-112","journal-title":"Ration Pharmacother Cardiol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejphar.2013.03.022","volume":"707","author":"Kumazaki M.","year":"2013","unstructured":"Kumazaki M.; Ando H.; Ushijima K.; Fujimura A.; Comparative effects of statins on murine cardiac gene expression profiles in normal mice. Eur J Pharmacol 2013,707(1-3),71-77","journal-title":"Eur J Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1007\/s00018-006-6235-z","volume":"63","author":"Kaufmann P.","year":"2006","unstructured":"Kaufmann P.; T\u00f6r\u00f6k M.; Zahno A.; Waldhauser K.M.; Brecht K.; Kr\u00e4henb\u00fchl S.; Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006,63(19-20),2415-2425","journal-title":"Cell Mol Life Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/eci.12461","volume":"45","author":"Apostolopoulou M.","year":"2015","unstructured":"Apostolopoulou M.; Corsini A.; Roden M.; The role of mitochondria in statin-induced myopathy. Eur J Clin Invest 2015,45(7),745-754","journal-title":"Eur J Clin Invest"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1083\/jcb.150.6.1283","volume":"150","author":"Milner D.J.","year":"2000","unstructured":"Milner D.J.; Mavroidis M.; Weisleder N.; Capetanaki Y.; Desmin cytoskeleton linked to muscle mitochondrial distribution and respiratory function. J Cell Biol 2000,150(6),1283-1298","journal-title":"J Cell Biol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0002-9440(10)63364-0","volume":"165","author":"Zemljic-Harpf A.E.","year":"2004","unstructured":"Zemljic-Harpf A.E.; Ponrartana S.; Avalos R.T.; Jordan M.C.; Roos K.P.; Dalton N.D.; Phan V.Q.; Adamson E.D.; Ross R.S.; Heterozygous inactivation of the vinculin gene predisposes to stress-induced cardiomyopathy. Am J Pathol 2004,165(3),1033-1044","journal-title":"Am J Pathol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/cddis.2012.61","volume":"3","author":"Ghavami S.","year":"2012","unstructured":"Ghavami S.; Yeganeh B.; Stelmack G.L.; Kashani H.H.; Sharma P.; Cunnington R.; Rattan S.; Bathe K.; Klonisch T.; Dixon I.M.C.; Freed D.H.; Halayko A.J.; Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts. Cell Death Dis 2012,3(6),e330","journal-title":"Cell Death Dis"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"806081","DOI":"10.3389\/fcell.2022.806081","volume":"10","author":"Zhang Q.","year":"2022","unstructured":"Zhang Q.; Qu H.; Chen Y.; Luo X.; Chen C.; Xiao B.; Ding X.; Zhao P.; Lu Y.; Chen A.F.; Yu Y.; Atorvastatin induces mitochondria-dependent ferroptosis via the modulation of Nrf2-xCT\/GPx4 Axis. Front Cell Dev Biol 2022,10,806081","journal-title":"Front Cell Dev Biol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"Sattar N.","year":"2010","unstructured":"Sattar N.; Preiss D.; Murray H.M.; Welsh P.; Buckley B.M.; de Craen A.J.M.; Seshasai S.R.K.; McMurray J.J.; Freeman D.J.; Jukema J.W.; Macfarlane P.W.; Packard C.J.; Stott D.J.; Westendorp R.G.; Shepherd J.; Davis B.R.; Pressel S.L.; Marchioli R.; Marfisi R.M.; Maggioni A.P.; Tavazzi L.; Tognoni G.; Kjekshus J.; Pedersen T.R.; Cook T.J.; Gotto A.M.; Clearfield M.B.; Downs J.R.; Nakamura H.; Ohashi Y.; Mizuno K.; Ray K.K.; Ford I.; Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010,375(9716),735-742","journal-title":"Lancet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.metabol.2014.02.014","volume":"63","author":"Brault M.","year":"2014","unstructured":"Brault M.; Ray J.; Gomez Y.H.; Mantzoros C.S.; Daskalopoulou S.S.; Statin treatment and new-onset diabetes: A review of proposed mechanisms. Metabolism 2014,63(6),735-745","journal-title":"Metabolism"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1517\/14740338.2015.1096343","volume":"14","author":"Agouridis A.P.","year":"2015","unstructured":"Agouridis A.P.; Kostapanos M.S.; Elisaf M.S.; Statins and their increased risk of inducing diabetes. Expert Opin Drug Saf 2015,14(12),1835-1844","journal-title":"Expert Opin Drug Saf"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/17512433.2019.1659133","volume":"12","author":"Yandrapalli S.","year":"2019","unstructured":"Yandrapalli S.; Malik A.; Guber K.; Rochlani Y.; Pemmasani G.; Jasti M.; Aronow W.S.; Statins and the potential for higher diabetes mellitus risk. Expert Rev Clin Pharmacol 2019,12(9),825-830","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/life11111175","volume":"11","author":"Chaulin A.M.","year":"2021","unstructured":"Chaulin A.M.; Elevation mechanisms and diagnostic consideration of cardiac troponins under conditions not associated with myocardial infarction. Part 2. Life 2021,11(11),1175","journal-title":"Life"}],"container-title":["Cardiovascular &amp; Hematological Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871525721666230314101019","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214602\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871525721666230314101019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T12:43:38Z","timestamp":1698410618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214602\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871525721666230314101019","relation":{},"ISSN":["1871-5257"],"issn-type":[{"type":"print","value":"1871-5257"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}